Market Overview

  • Global Huntington’s Disease Therapeutics Market is expected to grow at a CAGR of 38.7% during the forecasting period (2020-2027).
  • Huntington's disease is an inherited disease that causes the degeneration of nerve cells in the central nervous system (CNS). The disease has a broad impact on the functional abilities of the human and usually results in movement and thinking disabilities. Most people with Huntington's disease develop signs and symptoms in their age of 30 to 40. When disease begins before age 20, the condition is known as juvenile Huntington's disease. Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.
  • Both men and women are susceptible to this disease. Studies show that one in every 10,000 people in America has HD and more than 250,000 people are at risk of inheriting the disease from a parent.

Download free sample:

Market Dynamics

  • Huntington’s disease (HD) is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. HD accounts for approximately 30,000 cases annually in the U.S. and Juvenile HD accounts for nearly 16% of all cases. Both men and women are affected equally, and the prevalence is uniform between all races and ethnic groups.
  • Representing the developed world, the United States will maintain a YY.YY% growth momentum. Within Europe, which continues to remain an important element in the world economy, Germany will add over US$94.5 Million to the region’s size and clout in the next 5 to 6 years. Over US$84.1 Million worth of projected demand in the region will come from the Rest of Europe markets. In Japan, Huntington Disease Therapeutics will reach a market size of US$129.5 Million by the close of the analysis period.
  • As the world’s second-largest economy and the new game-changer in global markets, China exhibits the potential to grow at YY. YY% over the next couple of years and add approximately US$591.8 Million in terms of addressable opportunity for the picking by aspiring businesses and their astute leaders. Presented in visually rich graphics are these and many more need-to-know quantitative data important in ensuring the quality of strategy decisions, be it entry into new markets or allocation of resources within a portfolio.
  • Several macroeconomic factors and internal market forces will shape the growth and development of demand patterns in emerging countries in Asia-Pacific, Latin America, and the Middle East. All research viewpoints presented are based on validated engagements from influencers in the market, whose opinions supersede all other research methodologies.
  • Currently, only two symptom-alleviating therapies are specifically approved for HD: Xenazine and Austedo. The market is witnessing a shift in terms of a drug-development approach from conventional symptomatic therapies to disease-modifying therapies, driven by a better understanding of the pathogenesis of this disorder. The rapid uptake of improved symptomatic therapies and pipeline breakthroughs will remain the major factor driving the market over the next few years.
  • The clinical depression associated with Huntington's disease may increase the risk of suicide. Some research suggests that a greater risk of suicide occurs before a diagnosis is made and in the middle stages of the disease when a person has begun to lose independence. Eventually, a person with Huntington's disease requires help with all activities of daily living and care. Late in the disease, he or she will likely be confined to a bed and unable to speak. However, a person's understanding of surroundings and interactions remain intact for a long time.

Market Segmentation Analysis

  • In recent times, an unmet medical need is the key driver of the global Huntington’s disease therapeutics market. Increased pharmaceutical R&D investment and the introduction of innovative drugs have also fueled the growth of global Huntington’s disease therapeutics market. This is due to less number of curative drugs has led manufacturers to increase investment in R&D for the development of innovative solutions to treat Huntington’s disease.
  • Extensive pipeline drugs with properties, such as high patient compliance and improved safety, are also supporting the growth of global Huntington’s disease therapeutics market. Alternative therapies, such as psychotherapy, speech therapy, and physiotherapy hold immense potential to the growth of global Huntington’s disease therapeutics market.
  • Huntington's disease Therapeutics market segment by type covers Antidopaminergics, Anticonvulsants, Antipsychotics, and Antidepressants
  • Unusually high levels of dopamine are thought to cause chorea (involuntary jerking or writhing movements) in Huntington’s patients. Toward later stages of the disease, however, dopamine levels can drop notably. Unusually low dopamine levels ease chorea but cause such Parkinson’s disease-like symptoms as akinesia, the loss of the ability to move muscles voluntarily.
  • Antidopaminergic agents are used to easing chorea symptoms, but may also accelerate disease progression by reducing dopamine’s action to below a critical level.
  • Xenazine (tetrabenazine) and Austedo (deutetrabenazine) are two antidopaminergic medications approved by the U. S. Food and Drug Administration (FDA) to treat symptoms of chorea in Huntington’s disease. They work by blocking VMAT proteins and dopamine receptors. Austedo’s chemical structure is similar to Xenazine, but it is more stable.
  • Antipsychotic agents with a therapeutic effect in Huntington’s disease also work through an antidopaminergic mechanism. Antipsychotic agents reduce chorea and may also ease psychiatric symptoms, behavioral disturbances, and cognitive difficulties in Huntington’s patients.
  • AbilityHaldol (haloperidol) is a conventional antipsychotic medication. It has been shown to improve chorea symptoms, but its use is known to carry several side effects. Second-generation antipsychotic medications, known as atypical antipsychotics, are thought to be better tolerated than conventional agents, with fewer Parkinson’s-like side effects. These medications may include Risperdal (risperidone), Zyprexa (olanzapine), Seroquel (quetiapine), Geodon (ziprasidone), and Abilify (aripiprazole). Most of these medications work through multiple mechanisms, and not just as antidopaminergic agents.

Market Geographical Analysis

  • Geographically, the global Huntington’s disease therapeutics market is distributed over North America, Europe, APAC, and Latin America. North America dominates the global market due to increased awareness about the disease. In the North American market, the U.S. holds the largest market share, followed by Canada.
  • Europe accounts for the second-largest market globally. In Europe, countries such as France, Germany, the U.K., and Spain contribute major shares of the market. Increasing awareness about the disease along with growing infrastructure for scientific research is projected to lead to the market establishment for Huntington’s disease therapeutics in other parts of the world such as China, India, Japan, Africa, Argentina, and Brazil.

Market Competitive Trends

  • Key players contributing highest market shares include Teva Pharmaceutical Industries, Alnylam Pharmaceuticals, Inc., AmpliPhi Biosciences Corp, Pfizer, Lundbeck, Prana Biotechnology Ltd., Valeant Pharmaceuticals International Inc., Cortex Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, GlaxoSmithKline, Auspex Pharmaceuticals, Ceregene Inc., SOM Biotech, Siena Biotech, Raptor Pharmaceutical, Palobiofarma, and Ipsen.
  • The U.S. Food and Drug Administration (FDA) has given fast track designation to AMT-130, uniQure’s gene therapy candidate for the treatment of Huntington’s disease.
  • AMT-130 is an experimental gene therapy designed to block the production of the mutated form of the huntingtin (HTT) protein, the underlying cause of Huntington’s disease. It consists of a small portion of synthetic genetic material, called microRNA (miRNA), which binds to the RNA messenger molecule carrying the genetic information needed to make the huntingtin protein, marking it for elimination. As a result, gene therapy prevents the production of a faulty HTT protein.

View full report:

Enquiry before buying:

About Us

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866